LEO Pharma Inc. is a wholly-owned subsidiary of the LEO Foundation of Denmark. The Foundation is an independent Research Foundation specializing in dermatology, hemostasis and inflammation. The dermatology portfolio includes, Topical Fucidin*, which is today the highest prescribed topical antibiotic in Canada, Dovobet*/ Dovonex*, leading treatments for psoriasis over the past 12 years, as well as Fucidin*H for mild to moderate Atopic Dermatitis.

The LEO Foundation prides itself in it ’s’ ability to generate the highest quality of research to support its product claims. This has been accomplished through an active network of world-class researchers, including more than 200 dermatologists within the Canadian healthcare system.

*registered trademark of LEO Pharmaceutical Products used under license by LEO Pharma Inc., Thornhill, Ontario

Click here to close this window
and return to the Dermatology Update Sponsors Page.